Trends in Pharma Enforcement and Compliance
|
|
|
- Winfred Boyd
- 6 years ago
- Views:
Transcription
1 Pharmaceutical Compliance Forum Trends in Pharma Enforcement and Compliance September 15, 2009
2 Discussion Topics Key Enforcement Trend: Beyond Sales and Marketing Compliance Trends Oversight and Accountability Tracking & Monitoring (Embedding Compliance) Responding to Potential Misconduct Transparency & Disclosure Questions and Answers PCF: Trends in Pharma Enforcement & Compliance 2
3 Cautionary Notes Company-specific citations in slide and accompanying discussion based on public sources no privileged or confidential information With respect to discussion of indictments and/or civil FCA allegations, these involve allegations of wrongful conduct and are not themselves proof In each of the civil settlements, the company s have denied wrongdoing and the settlements do not include admissions of liabilities The purpose of today s discussion is to describe and analyze theories of liability/risks (and potential defenses and mitigation strategies) not to judge or criticize the conduct of any particular company PCF: Trends in Pharma Enforcement & Compliance 3
4 FCA Complaint Forest Laboratories PCF: Trends in Pharma Enforcement & Compliance 4
5 Forest Laboratories (cont d) PCF: Trends in Pharma Enforcement & Compliance 5
6 Forest Laboratories (cont d) PCF: Trends in Pharma Enforcement & Compliance 6
7 Forest Laboratories (cont d) PCF: Trends in Pharma Enforcement & Compliance 7
8 Forest Laboratories (cont d) PCF: Trends in Pharma Enforcement & Compliance 8
9 Forest Laboratories (cont d) PCF: Trends in Pharma Enforcement & Compliance 9
10 Forest Laboratories (cont d) PCF: Trends in Pharma Enforcement & Compliance 10
11 Forest Laboratories (cont d) Activities/evidence regarding off-label and/or inducements promotion: Marketing plans and forecasts Sales force call plans Promotional speakers Advisory boards Clinical study with alleged purpose to switch patients Preceptorships Ghostwriting Gifts and entertainment ROI analysis Complaint also makes reference to prior compliance statements by management PCF: Trends in Pharma Enforcement & Compliance 11
12 FCA Complaint in U.S. v. Scios Filed June 11, 2009 Focuses on Natrecor (approved IV treatment for acute decompensated CHF Alleges promotion for serial, scheduled out-patient infusions Qui tam complaint filed in 2005 by former Area Manager PCF: Trends in Pharma Enforcement & Compliance 12
13 Scios Complaint Overview Activities/evidence regarding off-label promotion: Internal marketing materials discussing the outpatient market, opportunity Sales force calls on outpatient infusion clinics Payments to HCPs for promotional speeches, training on outpatient use, publications on use in outpatient setting Ghostwriting Use of CME to promote off-label use Registry study conducted as a marketing tool Coverage and reimbursement support DOJ refers to company-sponsored studies indicating Natrecor was not effective for serial, out-patient infusions ( 48-54) Discussion of Scios/J&J relationship PCF: Trends in Pharma Enforcement & Compliance 13
14 Scios Complaint Points to Consider No allegation of false or misleading statements Substantial discussion of coverage and reimbursement activities ( 91-97) PCF: Trends in Pharma Enforcement & Compliance 14
15 PCF: Trends in Pharma Enforcement & Compliance 15
16 Insights and Analysis Scrutiny of how companies compile and disclose clinical study results. While often characterized as involving false and misleading communications, many do not involve outright falsehoods; rather, they are premised on communications that are misleading by omission of contrary or negative study data. Despite controversy over prosecution of truthful, non-misleading offlabel promotional activities by manufacturers, DOJ actions generally have focuses allegations of false and misleading statements made with intent to defraud. The Scios complaint is a notable exception, though DOJ may narrow its focus as the case proceeds. Prosecutors are scrutinizing "traditional" sales and marketing practices, including "ghostwriting," reimbursement support activities and interactions with compendia, formulary sponsors, and payor organizations. PCF: Trends in Pharma Enforcement & Compliance 16
17 Key Take-Aways Given DOJ approach of viewing individual acts (which themselves might not be unlawful) as part of broader scheme to defraud or mislead, compliance and risk strategies should look holistically at categories of activities (and overall product marketing plans/activities) rather than viewing individual activities/programs in isolation Manufacturers should expand compliance programs to cover risk-areas beyond traditional sales and marketing activities. Examples: Full range of clinical research and medical affairs activities, Activities involving coverage, reimbursement and payor interactions Tracking and other mechanisms to ensure on-going compliance with commitments made to FDA (such as in response to Warning or untitled letters, 483 responses, meetings with FDA review personnel). PCF: Trends in Pharma Enforcement & Compliance 17
18 Compliance Trends Last Year Board Oversight Management Accountability Transparency & Disclosure This Year More Intensity in Each of the Previous Areas Embedded Compliance Collection and Tracking Systems Monitoring and Auditing Responding to Internal Allegations of Misconduct PCF: Trends in Pharma Enforcement & Compliance 18
19 Compliance Trends Tracking & Monitoring PCF: Trends in Pharma Enforcement & Compliance 19
20 Compliance Trends Tracking & Monitoring PCF: Trends in Pharma Enforcement & Compliance 20
21 Internal Tracking & Monitoring Pfizer Serono S-P (2006) Purdue Jazz Cephalon Pfizer Review of Detailing Records (i.e., Verbatims) x x x x x Monitoring and Review of Requests for Off-Label Information Ride-Alongs x x x x x x x x x x Field Supervisor Monitoring x x Speaker Monitoring x x Call Notes and/or Sales Records Review x x Publication Monitoring x PCF: Trends in Pharma Enforcement & Compliance 21 21
22 Internal Investigations & Remediation PCF: Trends in Pharma Enforcement & Compliance 22 22
23 Internal Investigations & Remediation PCF: Trends in Pharma Enforcement & Compliance 23 23
24 Internal Investigations & Remediation PCF: Trends in Pharma Enforcement & Compliance 24 24
Off-Label Promotion: Risks, Controls and Assessment
7 th th Annual National Pharmaceutical Congress November 9, 2006 Off-Label Promotion: Risks, Controls and Assessment John T. Bentivoglio Co-Leader FDA/Healthcare Group jbentivoglio@kslaw.com 202.626.5591
American Academy of Orthopaedic Surgeons 2010 Annual Meeting
American Academy of Orthopaedic Surgeons 2010 Annual Meeting Off-Label Device Use: When Clinical Need Outpaces Regulatory Approval The Legal Parameters of Off-Label Use March 10, 2010 Kathleen McDermott
Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders
Rules of Engagement for MSLs - Appropriate Interactions with Internal and External Stakeholders Daniel Snyder, PhD Medical Director, Neurology North America Medical Affairs Ipsen Biopharmaceuticals, Inc.
THE OFF-LABEL DEBATE AND FDA S SHIFTING OUTLOOK
THE OFF-LABEL DEBATE AND FDA S SHIFTING OUTLOOK Bridget M. Lankford In House Counsel Christopher W. Wasson Partner Erin Colleran Partner April 25, 2018 In-House Counsel Conference 2 Agenda Legal and Regulatory
Recent Trends in Corporate Integrity Agreements Affecting Medical Communications and Non- Promotional Activities
Recent Trends in Corporate Integrity Agreements Affecting Medical Communications and Non- Promotional Activities Second Annual Q1 Medical Communications Conference (Boston, MA) Mahnu Davar Feb. 22, 2013
Managing Speaker Program Compliance Benchmarking and Best Practices
Managing Speaker Program Compliance Benchmarking and Best Practices 16th Pharmaceutical Compliance Congress and Best Practices Forum October 2015 1 With You Today Moderator Katherine Buckley, Advisory
2005 FRAUD ISSUES IN MEDICAL DEVICES. James G. Sheehan Associate U.S. Attorney
2005 FRAUD ISSUES IN MEDICAL DEVICES James G. Sheehan Associate U.S. Attorney 215-861-8301 Jim.Sheehan@usdoj.gov DISCLAIMER My opinions, not Department of Justice policy In cases where there has not been
PRESCRIPTION DRUG ENFORCEMENT AND COMPLIANCE ISSUES EFFECTS OF THE NEW MEDICARE DRUG PROGRAM
PRESCRIPTION DRUG ENFORCEMENT AND COMPLIANCE ISSUES EFFECTS OF THE NEW MEDICARE DRUG PROGRAM JIM SHEEHAN(EDPA) Jim.Sheehan@USDOJ.gov 215 861-8301 www.usao-edpa.com DISCLAIMER My opinions, not official
Amgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract
FDA Update on Oversight of Prescription Drug Promotion
FDA Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration November 7, 2018 Topics Medical Product Communications That
A Focus on Off-Label Issues
A Focus on Off-Label Issues Stephen F. Mohr Deputy Compliance Officer AstraZeneca Pharmaceuticals Sheryl Vacca West Coast Practice Leader Life Science Regulatory Practice Deloitte & Touche LLP Disclaimer
KADMON HOLDINGS, INC. BOARD OF DIRECTORS REGULATORY AND COMPLIANCE COMMITTEE
Purpose KADMON HOLDINGS, INC. BOARD OF DIRECTORS REGULATORY AND COMPLIANCE COMMITTEE Effective as of June 27, 2016 The Regulatory and Compliance Committee (the Committee ) is a committee of the Board of
Long-time OIG Chief Counsel, Lew Morris stepped down last. OIG Update
OIG Update VOL. XI, ISSUE 4/ OIG senior counsel offers key compliance take-aways from pharma compliance roundtable OIG s Riordan says industry places premium on flexibility in compliance programs The theme
Implementing a Compliance Monitoring Program. January 29, 2014
Implementing a Compliance Monitoring Program January 29, 2014 1 Agenda 1. Mission and Purpose 2. Scope 3. Situational Analysis 4. Best Practices 5. Questions Mission and Purpose 3 Mission and Purpose Mission
Compliance Plans. Kelly S. McIntosh July 20, 2017
Compliance Plans Kelly S. McIntosh July 20, 2017 Roadmap The importance of compliance and compliance programs Common compliance issues know your risk areas! Guidance for drafting or updating your compliance
Understanding the New Complexities of Clinical Trials from Results Reporting and FMV to Off-label Communication and Aggregate Spend
Understing New Complexities Clinical Trials from Results Reporting FMV Off-label Communication Aggregate Spend Mark DeWyngaert, Ph.D. Kathleen Tench Huron Consulting Group Life Sciences Advisory Services
ALI-ABA Video Law Review The False Claims Act: Including New Proposed Amendments Wednesday, April 30, 2008 Live Video Webcast
211 ALI-ABA Video Law Review The False Claims Act: Including New Proposed Amendments Wednesday, April 30, 2008 Live Video Webcast February 27, 2008, Written Testimony in Opposition to S. 2041: Chamber
Mini Summit XI: Third Party Management, including Pre-evaluation, Due Diligence, Contracting, Monitoring and Payment
Mini Summit XI: Third Party Management, including Pre-evaluation, Due Diligence, Contracting, Monitoring and Payment Shanghai 16:00 17:15 14 September, 2017 Disclaimer Please note that the views and opinions
WORKSHOP B Monitor MSL and Field Force Compliance
WORKSHOP B Monitor MSL and Field Force Compliance Jeremy Lutsky Sr. Legal & Compliance Counsel Theravance Biopharma US, Inc. Alison Benincasa Associate Director, Specialty Markets Compliance Christine
Airport Legal Governance Issues: Understanding & Meeting Ethics Compliance Obligations
Airport Legal Governance Issues: Understanding & Meeting Ethics Compliance Obligations presented by: Kevin Kraham Shareholder Washington, DC Office kkraham@littler.com 202.423.2404 Today s Agenda The Trends:
OPDP Update on Oversight of Prescription Drug Promotion
OPDP Update on Oversight of Prescription Drug Promotion Thomas Abrams Director Office of Prescription Drug Promotion Food and Drug Administration November 3, 2014 1 Topics Policy and Guidance Development
Arc of Onondaga Corporate Compliance Plan
Arc of Onondaga Corporate Compliance Plan The Corporate Compliance Plan consists of eight key elements as well as a wide array of policies and procedures that address key risk areas, to guide our best
Fourth Annual Pharmaceutical Regulatory and Compliance Congress
Fourth Annual Pharmaceutical Regulatory and Compliance Congress Preconference I A Compliance Primer for the Pharmaceutical Sector Michael P. Swiatocha November 12, 2003 Agenda for Preconference I Introduction
Compliance on the Road: Government and Industry Efforts to Monitor Field Force
Page 1 of 6 May 2011 Volume 7 Number 9 Compliance on the Road: Government and Industry Efforts to Monitor Field Force Compliance By Heather McCollum, Senior Consultant, Polaris Management Partners, New
BUILDING AN EFFECTIVE COMPLIANCE PROGRAM
BUILDING AN EFFECTIVE COMPLIANCE PROGRAM April 22, 2010 Joseph L. Barloon Partner Litigation & Government Enforcement, Skadden Arps Slate Meagher & Flom LLP WMACCA Conference Julie A. Bell April 22, 2010
Conducting Effective Internal Investigations. From Workplace Harassment to Criminal Conduct and Everything in Between
Conducting Effective Internal Investigations From Workplace Harassment to Criminal Conduct and Everything in Between Presenters Christopher G. Keim Partner, Management Committee Chris is a trial lawyer
Operational Considerations for Transparency. September 2011
Operational Considerations for Transparency September 2011 Current Global Regulatory Trends Type of Regulations/ Guidance Company s obligations Scope Sanctions/ Penalties State Laws Promotional spend reporting
Compliance Strategies for Sample Management under PDMA
Compliance Strategies for Sample Management under PDMA Arjun Rajaratnam, GlaxoSmithkline Second Annual Pharmaceutical Industry Regulatory and Compliance Summit, June 11, 2001 1 Compliance Strategies for
Communicating Emerging Drug Therapies Prior to FDA Approval. May 4, 2017
Communicating Emerging Drug Therapies Prior to FDA Approval May 4, 2017 Michelle Drozd Deputy Vice President, Policy and Research Pharmaceutical Research Manufacturers Association (PhRMA) Michael Labson
GOODWILL INDUSTRIES OF COLORADO SPRINGS
GOODWILL INDUSTRIES OF COLORADO SPRINGS CORPORATE COMPLIANCE PROGRAM ADOPTED : By the Board of Directors Date: October 25, 2005 Attachment 2 Memorandum 10-41 TABLE OF CONTENTS Corporate Compliance Program
at the Center of Food and Drug Law
AVAILABLE ONLINE FREE TO MEMBERS WWW.FDLI.ORG ANNUAL CONFERENCE ISSUE MARCH/APRIL 2014 A PUBLICATION OF THE FOOD AND DRUG LAW INSTITUTE at the Center of Food and Drug Law A Primer on Conducting Effective
ARNOLD & PORTER UPDATE
ARNOLD & PORTER UPDATE Pharmaceutical Sales and Marketing Practices Government Also Cautions Medical Device Companies on Such Practices April 2003 On April 28, 2003, the Office of Inspector General, Department
1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 2, 2011 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville,
LONDON PUBLIC LIBRARY POLICY
PURPOSE: The purpose of the Fraud Policy and its accompanying Risk Management Plan is to establish a framework by which London Public Library (LPL) will practice the highest level of business integrity
Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM
Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM 1. Compliance with Law All colleagues, officers and directors of the Company shall respect and comply with all applicable federal, state, local and foreign
Presentation Overview
How to Reasonably & Effectively Implement Compliance Programs for Small Group Physician Practices Andrea Merritt, Director of Compliance & Audit Services Ashlie Heald, Compliance Specialist Nova Compliance
MEASURING & MONITORING RISK USING ANALYTICS
MEASURING & MONITORING RISK USING ANALYTICS APRIL 13, 2017 2017 HURON CONSULTING GROUP INC. PRESENTERS Brian Bohnenkamp Partner King & Spalding BBohnenkamp@KSLAW.com Jack Tanselle Managing Director Huron
Off-Label Use Congress and FDA must balance: The need to regulate manufacturer promotion of off-label use of devices; and The need for and availabilit
Off-Label Use Versus Clinical Trial Use of Devices: FDA Regulatory Issues Neil F. O Flaherty Principal Olsson Frank Weeda Terman Bode Matz PC Off-Label Use Uses that do not appear in a device s FDA-approved
Promotion & Advertising of Combination Products: Key Postmarket Considerations
Combination Products Regulation, Policy, & Best Practices It s A Whole New Ballgame Are You All In? June 8, 2017 Promotion & Advertising of Combination Products: Key Postmarket Considerations Moderated
The Company seeks to comply with both the letter and spirit of the laws and regulations in all countries in which it operates.
1. Policy Statement ROOT9B HOLDINGS, INC. CODE OF BUSINESS CONDUCT AND ETHICS The Nasdaq listing standards require that the Company provide a code of conduct for all of its directors, officers and employees.
Guide to North America Healthcare Compliance 2016/2017
Guide to North America Healthcare Compliance 2016/2017 Dr. Reddy s Laboratories, Inc. NOTICE: this information is provided pursuant to the requirements of California Health & Safety Code 119400, 119402,
Your Guide to the Compliance Process
Your Guide to the Compliance Process Our Commitment and Your Responsibilities Disciplinary Action Guidelines Guidance for Managers Investigations Process Overview US Reporting Process Overview Corporate
ICE 2016 Annual Conference Premiere Diamond Sponsor
ICE Premiere Diamond Sponsor ICE would like to recognize and thank the Premiere Diamond Sponsor of this year s conference and the audio podcast for this breakout session: www.medhok.com Compliance & Audit
DATA INTEGRITY INSPECTION PERSPECTIVES
DATA INTEGRITY INSPECTION PERSPECTIVES Mock Inspection - Thinking Discussion & Exercises Jay Waterbury and Loren Smith MMRC/MPRL/0013 07/2017 Overview and Objectives Introduction and Setup Data Integrity
Best Practices to Ensure Compliance with Scientific Exchange. Dennis Raglin, Partner Life Sciences Practice Group SEDGWICK LLP San Francisco 2015
Best Practices to Ensure Compliance with Scientific Exchange Dennis Raglin, Partner Life Sciences Practice Group SEDGWICK LLP San Francisco 2015 Scientific Exchange Unsolicited requests Unapproved use
Ryanair Holdings Limited
Ryanair Holdings Limited Code of Business Conduct & Ethics 2009 1 TABLE OF CONTENTS 1. INTRODUCTION 3 2. WORK ENVIRONMENT 3 2.1 Discrimination & Harassment 3 2.2 Privacy of Personal Information 3 2.3 Internet
ESTABLISHING EFFECTIVE CONTROL OVER SALES AND MARKETING ACTIVITIES. Tony Farino, Partner June 11, 2001
ESTABLISHING EFFECTIVE CONTROL OVER SALES AND MARKETING ACTIVITIES Tony Farino, Partner June 11, 2001 Establishing Effective Control Over Sales and Marketing Activities (Customer Engagement Activities)
Auditing: A Panel Discussion of Evolving Compliance Strategies
Auditing: A Panel Discussion of Evolving Compliance Strategies Ann E Lewis, VP and Senior Counsel, US Healthcare Law Compliance (Bristol-Myers Squibb) Monica Jonhart, Director, Auditing, US Healthcare
Strategies For Better Positioning Your Company To Do Business With The Federal Government
William Pannier, Esq. Pannier Law, P.C. Strategies For Better Positioning Your Company To Do Business With The Federal Government 8th Annual Southern California Small Business and Government Contracting
Cuyahoga County Division of Children and Family Services (CCDCFS) Policy Statement
Cuyahoga County Division of Children and Family Services (CCDCFS) Policy Statement Policy Chapter: Management Policy Number: 10.05.01 Policy Name: Reporting Misconduct Original Effective Date: 05/06/2008
Punishing Pharmaceutical Companies for Unlawful Promotion of Approved Drugs: Why the False Claims Act is the Wrong Rx
Georgetown University From the SelectedWorks of Vicki W Girard August 4, 2008 Punishing Pharmaceutical Companies for Unlawful Promotion of Approved Drugs: Why the False Claims Act is the Wrong Rx Vicki
DOJ Settles Two Major Off-Label Cases: Recent Settlements Highlight Array Of DOJ Enforcement Inquiries
Page 1 of 8 February 24, 2006 Articles & Analysis DOJ Settles Two Major Off-Label Cases: Recent Settlements Highlight Array Of DOJ Enforcement Inquiries By Meredith Manning, Stefanie L. Solomon, Peter
Managing Risk with Third Parties and Strategic Partners
Pharmaceutical Regulatory and Compliance Congress and Best Practices Forum Managing Risk with Third Parties and Strategic Partners State Law Compliance The Overview November 8, 2007 Paul J. Silver Managing
Delta Dental of Michigan, Ohio, and Indiana. Compliance Plan
Delta Dental of Michigan, Ohio, and Indiana Compliance Plan Procedure #: 420-29 Issue Date: 5/15/2013 Last Revised Date: 5/23/2016 Last Review Date: 5/23/2016 Next Review Date: 5/23/2017 Title: Compliance
7/20/2016. Disclaimer
Disclaimer Organizations may not re-use material presented at this AMCP webinar for commercial purposes without the written consent of the presenter, the person or organization holding copyright to the
CODE OF ETHICS AND PROFESSIONAL CONDUCT
CODE OF ETHICS AND PROFESSIONAL CONDUCT Preamble Members of The American Institute of Architects are dedicated to the highest standards of professionalism, integrity, and competence. This Code of Ethics
University Business Classification Scheme
University Business Classification Scheme Introduction The University Business Classification Scheme is a conceptual representation of an organisation s business. It describes an organisation s business
Current Topics at the Intersection of Medical and Marketing
Current Topics at the Intersection of Medical and Marketing November 16, 2004 This report is solely for the use of client personnel. No part of it may be circulated, quoted, or reproduced for distribution
Mount Sinai Health Partners and Initiatives Compliance Education
Mount Sinai Health Partners and Initiatives Compliance Education 2016 Audit and Compliance Services (ACS) Introduction 3 Welcome to the MSHP Compliance Education program The following presentation reviews
Responsible Conduct of Research: Managing Conflicts of Interest. Objectives
Responsible Conduct of Research: Managing Conflicts of Interest Conference for Effective Compliance Systems in Higher Education Larry Plutko and Bill Sacks Objectives Review the historical and legal background
COMPOUNDING PHARMACIES: STEPS TO AVOID ISSUES WITH THE FDA, DEA, PHARMACY BOARDS, AND PATENT HOLDERS. Denise Leard, Esq Brown & Fortunato, P.C.
COMPOUNDING PHARMACIES: STEPS TO AVOID ISSUES WITH THE FDA, DEA, PHARMACY BOARDS, AND PATENT HOLDERS Denise Leard, Esq. 2017 Brown & Fortunato, P.C. INTRODUCTION 2 INTRODUCTION In the fall of 2012, a meningitis
DISCLAIMER: EDUCATIONAL ONLY
Good Intentions Are Not Enough: How to Re-Energize Your Compliance Program Through Focus, Support, and Accountability 2016 TPCA ANNUAL LEADERSHIP CONFERENCE Adam J. Falcone, Esq. Partner DISCLAIMER: EDUCATIONAL
Off-Label DTC Advertising
September 2016 Vol. 15, No. 4 Pharma Marketing Network www.pharmamarketingnews.com Off-Label DTC Advertising Will FDA Be Forced to Allow It? Author: John Mack Published by: Pharma Marketing Network PMN1504-01
6/20/2016 BIOSIMILARS: US OVERVIEW JUNE 9, Shawn Brown, VP International Affairs Allergan Inc. DISCUSSION TOPICS
BIOSIMILARS: US OVERVIEW JUNE 9, 2016 Shawn Brown, VP International Affairs Allergan Inc. DISCUSSION TOPICS Current Market BSUFA Negotiations Medicare Part D + CMS Reimbursement Legal Questions (Amgen
Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration
Kathy Weil Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health US Food and Drug Administration Kathy.Weil@fda.hhs.gov Follow the protocol and IDE regulations
Jefferson Hills Corporate Compliance Program
Our Mission Jefferson Hills provides safe and supportive treatment programs and learning environments, preparing children, adolescents, and families in need of mental health, human services, and/or youth
PUBLIC AUTHORITY BOARD MEMBER DUTIES Anita Laremont, SVP - Legal & General Counsel Empire State Development Corporation December 2005
PUBLIC AUTHORITY BOARD MEMBER DUTIES Anita Laremont, SVP - Legal & General Counsel Empire State Development Corporation December 2005 I. The duties and legal responsibilities of board of director members
The criminal division at the Department of Justice is now building cases against drug companies by
VOL. VIII, ISSUE 8/ DOJ s Deputy Fraud chief outlines bottom-up approach to building pharma fraud cases New approach puts initial focus of investigations on physicians and individual employees, says DOJ
Too Much of a Good Thing?
Regulatory s Role in Reviewing External Corporate Communications Too Much of a Good Thing? By John Driscoll Every regulatory professional is a reviewer. One could even say that the majority of our work
Managing Compliance Risk in M&A, and Special Considerations for Joint Ventures
Managing Compliance Risk in M&A, and Special Considerations for Joint Ventures SCCE Upper Midwest Regional Conference April 26, 2013 Agenda Compliance risk and threat landscape overview Four areas we ll
Medical Device Communiqué
Medical Device Communiqué Q2 2013 Demonstrating the Safety of Medical Devices in the Human Body 1 DOJ: The Focus is on GMPs in 2013 2 ROHS II Impacts Medical Device Companies 3 Demonstrating the Safety
Authorship and Algorithms: Assessing Authorship at Lilly. Jeffrey W. Clemens, Ph.D. Eli Lilly and Company
Authorship and Algorithms: Assessing Authorship at Lilly Jeffrey W. Clemens, Ph.D. Eli Lilly and Company 1 Disclosure I am an employee and stockholder of Eli Lilly and Company. Eli Lilly and Company has
New Trends in the Use of Fair Market Value Concepts. PCF Disclosure, Transparency, and Aggregate Spend Conference February 6, 2014
New Trends in the Use of Fair Market Value Concepts PCF Disclosure, Transparency, and Aggregate Spend Conference February 6, 2014 Agenda Today s Speakers 4 Today s Discussion Topics 6 Question and Answer
CODE OF BUSINESS CONDUCT AND ETHICS
1 ST FRANKLIN FINANCIAL CORPORATION CODE OF BUSINESS CONDUCT AND ETHICS Introduction This Code of Business Conduct and Ethics ( Code ) describes the basic principles of conduct that we share as officers
201 Fraud Risk Assessment April 19, 2010 Monday 1:30 2:30 pm Paul M. Baran Mark P. Ruppert, CPA, CIA, CISA, CHFP. Round Up!
201 Fraud Risk ment April 19, 2010 Monday 1:30 2:30 pm Paul M. Baran Mark P. Ruppert, CPA, CIA, CISA, CHFP Director, Internal Audit Director, Internal Audit Fraud Risk ment Round Up! Why? What is Fraud
The Company seeks to comply with both the letter and spirit of the laws and regulations in all jurisdictions in which it operates.
1. Policy Statement CRC HEALTH GROUP, INC. CRC HEALTH CORPORATION CODE OF BUSINESS CONDUCT AND ETHICS It is the policy of CRC Health Group to conduct its business affairs honestly and in an ethical manner.
Managing Conflicts of Interest in the Pharmaceutical Sector
Managing Conflicts of Interest in the Pharmaceutical Sector Marc A. Rodwin, J.D., Ph.D. Professor of Law, Suffolk University Law School Boston, MA 02140, U.S.A. marcrodwin@gmail.com Implementing the access
New DOJ Charging and Sentencing Guidance and Amendments to the Sentencing Guidelines May Heighten the Value of an Effective Compliance Program
New DOJ Charging and Sentencing Guidance and Amendments to the Sentencing Guidelines May Heighten the Value of an Effective Compliance Program Tony Alexis Partner 202 263 3450 aalexis@mayerbrown.com Paula
May 2, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
Approval Requirement Version No 1.0 Date December 2012 Next Review January Change Record
Whistle Blowing Policy A whistle blowing policy is about the ways in which concerns about malpractices may properly be raised within the company and where necessary outside, whilst protecting the whistle
Code of Conduct. 1 P age
Code of Conduct 2013 1 P age Dear Colleagues, At INSYS, we believe in doing the right thing for our patients, customers, employees, communities and business partners. Our patients and customers trust the
Mini Summit IV: Advanced Issues in Transparency and Disclosure - Research and Clinical Trials Update
Mini Summit IV: Advanced Issues in Transparency and Disclosure - Research and Clinical Trials Update Dr. Jessica Santos Global Compliance and Quality Director 17 August 2015 Meaning of Pharma/Life Science
Enterprise Research Risk
Enterprise Research Risk Managing All the Moving Parts Erika Stevens, MA, Senior Manager Healthcare Advisory Tina Noonan, MBA,CHRC,CIP Director, Research and Regulatory Affairs Learning objectives Describe
CORPORATE COMPLIANCE PLAN
CORPORATE COMPLIANCE PLAN PEOPLE INC. CORPORATE COMPLIANCE PLAN May 2015 People Inc. and its affiliates (collectively, the Agency ) have adopted a Corporate Compliance Program ( Compliance Program ) to
Addressing Key FDA Citations with Training. Align UL EduNeering Courses to Top FDA Warning Letter Topics
Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter Topics Addressing Key FDA Citations with Training Align UL EduNeering Courses to Top FDA Warning Letter
A. Establish compliance standards and system-wide policies and procedures;
WellSpan Health Manual of Administrative Policy Page 1 of 10 PURPOSE The WellSpan Health Compliance Program (Program) has been designed, adopted (1999), and implemented as a voluntary program to address
Tales from the Trenches: BSA/AML Independent Audit Lessons. Juan Azel, Counsel, Hunton & Williams LLP
Tales from the Trenches: BSA/AML Independent Audit Lessons Juan Azel, Counsel, Hunton & Williams LLP The Trench Senior Legal Regulatory Counsel for Standard Chartered Bank, NY (SCB) from 2012 to 2016.
Sunshine Act and Beyond: Improving Policies and Strategies
Helping companies identify and manage their compliance and commercial risk. C O M P L I A N C E IMPLEMENTATION SERVICES Sunshine Act and Beyond: Improving Policies and Strategies Presented by Vahan Minassian,
ACTA Anti-corruption, transparency and accountability in the health sector
ACTA Anti-corruption, transparency and accountability in the health sector Implications for health system assessments, national health planning and health system strengthening efforts Incorporating ACTA
Internal Audit & Compliance Importance of Collaboration and Skill Development
Internal Audit & Compliance Importance of Collaboration and Skill Development Odell Guyton Director of Compliance Microsoft Corporation Co-Chair Society Corporate Compliance & Ethics Austin, Texas June
Company LOGO C B T. An Educational Computer Based Training Program
C B T An Educational Computer Based Training Program The University of Texas at Dallas Compliance Training Effectively Controlling Risks Company Effectively Controlling Risks What is the purpose of this
DOUBLE-TAKE SOFTWARE, INC. CODE OF BUSINESS CONDUCT AND ETHICS
DOUBLE-TAKE SOFTWARE, INC. CODE OF BUSINESS CONDUCT AND ETHICS This Code of Business Conduct and Ethics covers a wide range of business practices and procedures and serves as a guide to ethical decision-making.
Advertising and Marketing Genetic Tests New Pathways or Old Roads?
Advertising and Marketing Genetic Tests New Pathways or Old Roads? Kathleen M. Sanzo, Morgan Lewis FDLI Advertising & Promotion Conference Wednesday, September 28, 2016 Context for Use of Genetic Tests
Regulatory Considerations and Evolving Issues Concerning REMS Programs
Regulatory Considerations and Evolving Issues Concerning REMS Programs Kathleen M. Sanzo ksanzo@morganlewis.com 202-739 739-5209 August 2009 1 Evolution of Risk Management AT FDA 1976 Patient package inserts
Contract and Procurement Fraud. Detection and Prevention
Contract and Procurement Fraud Detection and Prevention Introduction Procurement schemes have certain characteristics that make them particularly difficult to detect and prevent. Organizations can protect
Promoting Medical Products Globally
Promoting Medical Products Globally Handbook of Pharma and MedTech Compliance BRAZIL This publication is copyright. Apart from any fair dealing for the purpose of private study or research permitted under
Finance Code of Conduct
Finance Code of Conduct Finance Code of Conduct Purpose and Scope of Code Conduent Finance personnel are relied upon by Company management to: Develop honest and accurate financial statements; Safeguard
CDM Smith Code of Ethics
CDM Smith Inc. and all of its subsidiaries are committed to ethical conduct in our business practices. Since the firm s founding in 1947, we have always upheld a policy to conduct all business in a lawful
Standards for Excellence Program Organizational Self-Assessment Checklist
Standards for Excellence Program Organizational Self-Assessment Checklist Instructions for using the checklist: if the organization has met the standard, X if the organization has not met the standard,
It s time to revisit your anti-corruption compliance program How to design an effective and defensible compliance program in response to global trends
It s time to revisit your anti-corruption compliance program How to design an effective and defensible compliance program in response to global trends Many legal and compliance officers are revisiting